Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' development activities for voreloxin, including enrollment and reporting of results, could be halted significantly or delayed for various reasons; the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval; the risk that preliminary data and trends may not be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; and risks related to the conduct of Sunesis' clinical trials and manufacturing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Contacts:                                Media Contact:
    Sunesis Pharmaceuticals, Inc.            Invigorate Communications
    Eric Bjerkholt                           Monique Greer
    650-266-3717                             415-946-1075


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... MOUNTAIN VIEW, Calif. , Oct. 31, 2014 /PRNewswire/ ... amyotrophic lateral sclerosis (ALS) patients initiate text and email ... based upon a patent-pending technology invented by ThynkWare,s founder, ... virtual assistant on a smartphone device. This technology allows ... ways using only the power of thought. ...
(Date:10/31/2014)... 2014 Migranade, Inc. announced today the new ... the 36 million U.S. migraine sufferers November, 2014. The ... the actual cause of migraines and not just the ... the source Migranade is assured to be a game ... is available at http://www.migranade.com and will soon ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2
... 16, 2011  Senior citizens and people living with physical ... power wheelchairs if the Administration enacts a restrictive prepayment ... Medicare system, according to consumer advocates and home medical ... Centers for Medicare and Medicaid Services (CMS) has listed ...
... 16, 2011  Veran Medical Technologies announced today the ... bi-planar virtual fluoroscopy view used to navigate multiple ... its kind in pulmonology, enabling physicians to view ... in a fluoro-like view without any radiation being ...
Cached Medicine Technology:Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 2Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 3Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 4Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View 2
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... October 31, 2014 Energy Textiles has ... The new gear is now available online, and Energy ... benefits of Celliant infrared-active athletic gear over compression gear. ... another contract has been signed for Under Armour to ... the next eight years. In light of this decision, ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... ( www.PatientAssistance.com ) has released initial survey results on diabetes ... ... Baton Rouge, LA – November 20, 2008 – ... awareness amongst the predominantly uninsured and underinsured visitors of ...
... Amy Rees Anderson, was invited to participate with U.S. Secretary of ... Care. , ... Salt Lake City (Vocus) November 20, ... with U.S. Secretary of Health, Michael Leavitt, in the 2008 National ...
... for the prestigious "Super Dentist" award given to elite dentists in ... top practitioner in the area of Cosmetic Dentistry. , ... ... Austin Smiles was recently nominated as a "Texas Monthly ...
... the frequency of exacerbations in patients with moderate to ... as 35 percent, according to a London-based study. ... macrolide therapy, reducing exacerbation frequency and severity with moderate ... Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., ...
... NEW YORK Nov. 19, 2008 The American ... and largest non-governmental funder of cancer research and discovery ... Honor, to four Americans who have made outstanding contributions ... will receive their awards at a ceremony during the ...
... says about 40% returned positive results in review of ... Colorectal cancer screening detects 40 percent of cancers and ... Finnish Cancer Registry researchers. , They studied 106,000 people, ... colorectal cancer screening program was in identifying unrecognized disease. ...
Cached Medicine News:Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: